The evidence doesn't justify steps by state medicaid programs to restrict opioid addiction treatment with buprenorphine

Health Affairs

Volumn 30, Issue 8, 2011, Pages 1425-1433

  Clark, Robin E ^a   Samnaliev, Mihail ^b   Baxter, Jeffrey D ^a   Leung, Gary Y ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c North Carolina Central Cancer Registry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; DRUG COST; DRUG USE; FEMALE; HEALTH CARE ACCESS; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MORTALITY; OPIATE ADDICTION; PRESCRIPTION; ADOLESCENT; AGED; ECONOMICS; FACTUAL DATABASE; INSURANCE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; BUPRENORPHINE; DATABASES, FACTUAL; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MASSACHUSETTS; MEDICAID; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; UNITED STATES; YOUNG ADULT;

EID: 84855175907     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2010.0532     Document Type: Article

References (23)

1. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363(21):1981-4.
2. William BC, Fiellin DA, Merrill JO, Schulman B, Finkelstein R, Olsen Y, et al. Opioid use disorder in the United States: insurance status and treatment access. Drug Alcohol Depend. 2008;94(1-3):207-13.
3. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209.
4. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Sys Rev. 2008(2):CD002207.
5. Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007;1(2):62-7.
6. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001; 96(5):683-90.
7. Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: reaching new patient populations. Am J Psychiatry. 2001;158(8):1200-4.
8. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend. 2005;79(1):113-6.
9. Substance Abuse and Mental Health Services Administration. The SAMHSA evaluation of the impact of the DATA waiver program: summary report [Internet]. Rockville (MD): SAMHSA; 2006 [cited 2009 Sep 1]. Available from: http:// buprenorphine.samhsa.gov/FOR_ FINAL_summaryreport_colorized .pdf
10. Kuehn BM. Office-based treatment for opioid addiction achieving goals. JAMA. 2005;294(7):784-6.
11. National Conference of State Legislatures. 50-state table: Medicaid financing of medication-assisted treatment for opiate addiction [Internet]. Washington (DC): NCSL; 2008 Apr 1 [cited 2009 Sep 10]. Available from: http://www .ncsl.org/default.aspx?tabid=14144#32
12. Laine C, Lin YT, Hauck WW, Turner BJ. Availability of medical care services in drug treatment clinics associated with lower repeated emergency department use. Med Care. 2005;43(10):985-95.
13. Laine C, Hauck WW, GourevitchMN, Rothman J, Cohen A, Turner BJ. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA. 2001;285(18): 2355-62.
14. Kronick R, Gilmer T, Dreyfus T, Lee L. Improving health-based payment for Medicaid beneficiaries: CDPS. Health Care Financ Rev. 2000;21(3):29-64.
15. Clark RE, Samnaliev M, McGovern MP. The impact of substance use disorders on medical expenditures for Medicaid beneficiaries with behavioral health disorders. Psychiatric Serv. 2009;60(1):43-9.
16. Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, et al. Extended vs shortterm buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008; 300(17):2003-11.
17. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med. 1998;17(19):2265-81.
18. Basu A, Paltiel AD, Pollack HA. Social costs of robbery and the costeffectiveness of substance abuse treatment. Health Econ. 2001; 17(8):927-46.
19. Ettner SL, Huang D, Evans E, Ash DR, Hardy M, Jourabchi M, et al. Benefit-cost in the California treatment outcome project: does substance abuse treatment pay for itself? Health Serv Res. 2006;41(1): 192-213.
20. McCollister KE, French MT. The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings. Addiction. 2003;98(12):1647-59.
21. Caldiero RM, Theodore VP Jr., Adelman CL, Piche B. Inpatient initiation of buprenorphine maintenance vs detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? Am J Addict. 2006;15(1):1-7.
22. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000; 283(10):1303-10.
23. Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend. 1998;52(3):257-60.